TBCRC026: Phase II trial correlating standardized uptake value with pathologic complete response to pertuzumab and trastuzumab in breast cancer
- Roisin M. Connolly
- , Jeffrey P. Leal
- , Lilja Solnes
- , Chiung Yu Huang
- , Ashley Carpenter
- , Katy Gaffney
- , Vandana Abramson
- , Lisa A. Carey
- , Minetta C. Liu
- , Mothaffar Rimawi
- , Jennifer Specht
- , Anna Maria Storniolo
- , Vicente Valero
- , Christos Vaklavas
- , Ian E. Krop
- , Eric P. Winer
- , Melissa Camp
- , Robert S. Miller
- , Antonio C. Wolff
- , Ashley Cimino-Mathews
- Johns Hopkins University
- Vanderbilt University
- University of North Carolina at Chapel Hill
- Mayo Clinic Rochester, MN
- Baylor College of Medicine
- University of Washington
- Indiana University-Purdue University Indianapolis
- University of Texas MD Anderson Cancer Center
- University of Alabama at Birmingham
- Dana-Farber Cancer Institute
- Washington University St. Louis
Research output: Contribution to journal › Article › peer-review